

ASX ANNOUNCEMENT

Appendix 4C – Quarterly Cash Flow Report

29 April 2016: Analytica Ltd (ASX: ALT), manufacturer of the PeriCoach® system, today released its Appendix 4C – quarterly cash flow report for the quarter ended 31st March 2016.

Receiving overwhelming support from shareholders, the recent capital raising activity in April raised a combined total of approximately \$2,364k, comprising a \$1 million placement to Dr Michael Monsour at 0.3c per share, a shareholder purchase plan raising \$568k at \$0.00255 per share, and additional private placements of approximately \$280k and \$516k respectively.

This is a significant investment and places the Company in a very strong position to achieve its overall goal of securing a licensing deal with a major multinational corporation. The placement by Dr Monsour supports the recent decision by US Virgin Islands investor INOV8 LLC, to take up a 10% cornerstone investment in Analytica.

Both investments underline the confidence in Analytica's overall strategy, its significant achievements with advancing the PeriCoach and the Company's recent expenditure reduction initiatives.

With Dr Monsour's and INOV8 LLC's investment, Analytica believe they offer an attractive upside potential in securing a licensing agreement with a major medical device company with dedicated marketing and sales infrastructure, to make the product a global success. The principal behind INOV8 LLC, has a strong track record of major licence deals in the US and Europe.

During the quarter net operating cash flow was \$189k with receipts from sales of PeriCoach in Australia, UK and US totalling \$45k and in line with the previous quarter. The company also received an R&D tax credit of \$1.89 million. The cash balance at the end of the March quarter was \$145k, before capital raising.

As part of the cost cutting initiatives, Analytica has by mutual agreement, terminated its contract with Salesforce4Hire, its sales and marketing partner in the US. The company incurred one-off costs as a result of the early termination of this agreement as well as other one off costs of winding back marketing, but this means advertising and marketing costs will reduce significantly as of the June quarter in line with cost reduction targets. Advertising and marketing costs for the March quarter were \$566k, down from \$714k in the previous quarter.

Solid progress has been made during the quarter with the development of PeriCoach Version 3, which has added functionality designed to ensure the PeriCoach is the best-in-class product for urinary incontinence and other pelvic floor conditions. This version of the product, which is now in production, includes new sensors which may enable women to see whether they are performing their exercises correctly with every contraction. This version of the product incorporates feedback gained from users and clinicians collected over the past year, addressing a segment of the market that is currently not effectively served. R&D expenditure, which is largely associated with this product development, was \$629k, up from \$424k in the previous quarter. Recruitment into the company's post-approval clinical trial continues.



"Analytica is executing on its strategy to develop PeriCoach as best-in-class product. We are making strong progress with Version 3 and our immediate focus is on securing a licensing partner. The clinical data and user feedback continue to accumulate via our early user program and learnings in the market, which is valuable both in terms of product development and enhancing attractiveness to potential partners.

"We thank investors for their support of the recent share purchase plan and private placements. This additional capital, combined with our expenditure reduction program, provides a solid foundation of working capital to advance development," said Geoff Daly, CEO of Analytica.

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

Follow us on:



About Analytica Limited

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to PeriCloud where physicians can monitor patient progress via web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition.

PeriCoach has regulatory clearance in Australia, and has CE mark and USFDA 510(k) clearance. The product is available for sale in Australia and New Zealand, UK and Ireland, and in the USA by prescription.



Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/3/2000. Amended 30/9/2001

Name of entity

Analytica Limited

ABN

12 006 464 866

Quarter ended ("current quarter")

31/3/16

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (9 months) \$A'000
1.1 Receipts from customers	45	176
1.2 Payments for		
(a) staff costs	(372)	(1,064)
(b) advertising and marketing	(566)	(2,058)
(c) research and development	(629)	(1,343)
(d) leased assets	-	-
(e) other working capital	(190)	(758)
(f) realised currency gains	(9)	(45)
1.3 Dividends received	-	-
1.4 Interest and other items of a similar nature received	10	17
1.5 Interest and other costs of finance paid	(2)	(2)
1.6 Income taxes paid	-	-
1.7 Other-		
(a) Net sales income	-	-
(b) R & D Tax Concession	1,894	1,894
(c) Royalty Income	8	8
(d) Other Grant Income	-	-
Net operating cash flows	189	(3,175)

+ See chapter 19 for defined terms.

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

		Current quarter \$A'000	Year to date (9 months) \$A'000
1.8	Net operating cash flows (carried forward)	189	(3,175)
Cash flows related to investing activities			
1.9	Payment for acquisition of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	(3)	(10)
	(e) other non-current assets	-	-
1.10	Proceeds from disposal of:		
	(a) businesses	-	-
	(b) equity investments	-	-
	(c) intellectual property	-	-
	(d) physical non-current assets	-	-
	(e) other non-current assets	-	-
1.11	Loans to other entities	-	-
1.12	Loans repaid by other entities	-	-
1.13	Other (purchase of Convertible Notes)	-	-
	Net investing cash flows	(3)	(10)
1.14	Total operating and investing cash flows	186	(3,185)
Cash flows related to financing activities			
1.15	Proceeds from issues of shares	264	3,130
1.16	Proceeds from sale of forfeited shares	-	-
1.17	Proceeds from borrowings	-	278
1.18	Repayment of borrowings:	(278)	(278)
1.19	Dividends paid	-	-
1.20	Other Creditors (costs of fund raising)	(21)	(354)
	Net financing cash flows	(35)	2,776
	Net increase (decrease) in cash held	151	(409)
1.21	Cash at beginning of quarter/year to date	(6)	554
1.22	Exchange rate adjustments to item 1.20	-	-
1.23	Cash at end of quarter	145	145

+ See chapter 19 for defined terms.

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	133
1.25	Aggregate amount of loans to the parties included in item 1.11	-

1.26 Explanation necessary for an understanding of the transactions

Payment of director's fees and compulsory superannuation.

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

N/A

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

N/A

Financing facilities available

Add notes as necessary for an understanding of the position. (See AASB 1026 paragraph 12.2).

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	400	0
3.2	Credit standby arrangements	-	-

+ See chapter 19 for defined terms.

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	145	(6)
4.2 Deposits at call	-	-
4.3 Bank overdraft	-	-
4.4 Other (provide details)	-	-
Total: cash at end of quarter (item 1.23)	145	(6)

Acquisitions and disposals of business entities

	Acquisitions	Disposals
5.1 Name of entity	N/A	N/A
5.2 Place of incorporation or registration		
5.3 Consideration for acquisition or disposal		
5.4 Total net assets		
5.5 Nature of business		

Compliance statement

- 1 This statement has been prepared under accounting policies which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here:

Date: 29 April 2016

Print name: Ross Mangelsdorf

+ See chapter 19 for defined terms.